Advertisement

Mycopathologia

, Volume 104, Issue 3, pp 163–169 | Cite as

Persistence of infection in mice inoculated intranasally with Cryptococcus neoformans

  • D. Andy Anderson
  • Hossein M. Sagha
Article

Abstract

Cryptococcus neoformans was instilled intranasally into mice which were periodically sacrificed to determine the course of infection. Cryptococci persisted within the nasal passages throughout the 90 day study. Extranasal dissemination began 14–28 days after instillation and was still demonstrable 90 days post-exposure. Ten percent mortality was observed in mice receiving 106 cryptococci, while no mortality was observed in mice exposed to 103 or 104 cryptococci. Our research suggests that nasal colonization with C. neoformans can precede pulmonary and systemic cryptococcosis by weeks or months.

Key words

cryptococcosis Cryptococcus neoformans fungal disease nasal infection yeast infection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson DM, Dykstra MA. Pulmonary cell response in mice following intranasal instillation with Cryptococcus neoformans. Mycopathologia 1984; 86:179–84.Google Scholar
  2. 2.
    Bottone EJ, Wormser GD. Capsule-deficient cryptococci in AIDS. Lancet 1985; i:553.Google Scholar
  3. 3.
    Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987; 36(S-1):1-9.Google Scholar
  4. 4.
    Douglas RM, Hansman D, Miles HB, Paton JC. Pneumococcal carriages and type-specific antibody. Am J Dis Child 1986; 140:1183–5.Google Scholar
  5. 5.
    Dykstra MA, Friedman L. Pathogenesis, lethality, and immunizing effect of experimental cutaneous cryptococcosis. Infect Immunol 1978; 20:446–55.Google Scholar
  6. 6.
    Farhi F, Bulmer GS, Tacker JR. Cryptococcus neoformans — IV. The not-so-encapsulated yeast. 1970; 1:526–31.Google Scholar
  7. 7.
    Gadebusch HH. Native and acquired resistance to infection with Cryptococcus neoformans. In: Gadebusch HH, ed. Phagocytes and cellular immunity. Florida: CRC Press, 1979; 137–57.Google Scholar
  8. 8.
    Green GM, Jakab GJ, Low RB, Davis GS. Defense mechanisms of the respiratory membrane. Am Rev Resp Dis 1977; 115:479–514.Google Scholar
  9. 9.
    Hady MR, Hassan S, Hassan R. Nasal mucociliary function in different diseases. J Laryngeol Otol 1983; 97:497–502.Google Scholar
  10. 10.
    Lim TS, Murphy JW, Cauley LK. Host-etiological agent interactions in intranasally and intraperitoneally induced cryptococcosis in mice. Infect Immun 1980; 29:633–41.Google Scholar
  11. 11.
    Rippon JW, Cryptococcosis. In: Rippon JW, ed. Medical mycology. Philadelphia: WB Saunders Co., 1982:532–58.Google Scholar
  12. 12.
    Schimpff SC, Bennett JE. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol 1975; 55:430–41.Google Scholar
  13. 13.
    Karaqui RM, Hall NK, Larsh HW. Role of macrophages in immunity and pathogenesis of experimental cryptococcisis induced by the airborne route. Part I: Pathogenesis and acquired immunity of Cryptococcus neoformans. Mykosen 1977; 20:380–8.Google Scholar
  14. 14.
    Powel KE, Dahl BA, Weeks RJ, Tosh FE. Airborne Cryptococcus neoformans: particles from pigeon excreta compatible with alveolar deposition. J Infect Dis 1972; 125:412–5.Google Scholar
  15. 15.
    Ruiz A, Fromtling A, Bulmer GS. Distribution of Cryptococcus neoformans in a natural site. Infect Immun 1981; 31:560–3.Google Scholar
  16. 16.
    Wright GW. Structure and function of respiratory tract in relation to infection. Bactiol Rev 1961; 25:219–27.Google Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • D. Andy Anderson
    • 1
  • Hossein M. Sagha
    • 1
  1. 1.Biology DepartmentUtah State UniversityLoganUSA

Personalised recommendations